Mar 16, 2023 / 12:00PM GMT
Unidentified Analyst -
Thank you for joining us. My name is [Leon Wang], I'm a VP here covering SMid-Cap Biotech, and it's my pleasure to present Vivoryon -- Ulrich Dauer, the CEO. Ulrich, I'll pass it over to you.
Ulrich Dauer - Vivoryon Therapeutics N.V. - Chairman of the Management Board & CEO
Yes. Thank you very much for the kind introduction, and also thank you for making us part of the exciting program of Barclays Global Healthcare Conference.
When I joined Vivoryon back in 2018, so 5 years ago, the perception towards the field of Alzheimer's disease was mainly dominated by a series of expensive late stage failures in clinical trials and lack of new approvals for almost 2 decades. Fortunately, this situation has changed with Abeta antibodies like lecanemab and donanemab, which are increasing the excitement in all the field, industry attention, and they are increasing the hope by patients for novel treatments that can make a true difference to them.
I'm very pleased to have the opportunity today to explain why your attention should not only
Vivoryon Therapeutics NV at Barclays Global Healthcare Conference Transcript
Mar 16, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers